World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
115
Citations
124610
World Ranking
689
National Ranking
418

Medicine

D-Index
123
Citations
136859
World Ranking
3254
National Ranking
1795

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Julie R. Brahmer is affiliated with Johns Hopkins University in the United States and has a significant body of work within the field of Medicine. Their research focus primarily encompasses oncology, pulmonary and respiratory medicine, cancer research, molecular biology, and immunology.

The scientist's frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Journal of Thoracic Oncology
  • Journal for ImmunoTherapy of Cancer
  • Annals of Oncology

Julie R. Brahmer's main fields of study are:

  • Medicine

Within medicine, their subfields of study are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Molecular Biology
  • Immunology

The scientist's research covers multiple topics, including:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • CAR-T cell therapy research

Frequent coauthors collaborating with Julie R. Brahmer include:

  • Patrick M. Forde
  • Valsamo Anagnostou
  • Kristen A. Marrone
  • Jarushka Naidoo
  • Christine L. Hann

Notable recent papers authored or coauthored by Julie R. Brahmer include:

  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events, 2021, Journal for ImmunoTherapy of Cancer
  • Immune-related adverse events of checkpoint inhibitors, 2020, Nature Reviews Disease Primers
  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%, 2021, Journal of Clinical Oncology
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer, 2021, Journal of Clinical Oncology
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers, 2021, Nature

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

    Alan Sandler;Robert Gray;Michael C. Perry;Julie Brahmer

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

    Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

    Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Immune-related adverse events of checkpoint inhibitors.

    Manuel Ramos-Casals;Julie R. Brahmer;Margaret K. Callahan;Margaret K. Callahan;Alejandra Flores-Chávez

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Genome-wide cell-free DNA fragmentation in patients with cancer

    Stephen Cristiano;Alessandro Leal;Jillian Phallen;Jacob Fiksel

  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

    Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

Frequent Co-Authors

Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Scott N. Gettinger
Scott N. Gettinger Yale University
Scott J. Antonia
Scott J. Antonia Duke University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Janis M. Taube
Janis M. Taube Johns Hopkins University
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Victor E. Velculescu
Victor E. Velculescu Johns Hopkins University School of Medicine
Leora Horn
Leora Horn Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in healthcare but aren’t sure if a traditional medical degree is the right path, there are several high-demand alternatives to explore. Many prospective students choose to pursue roles as nurses, healthcare administrators, or medical billing specialists, each offering unique benefits and career flexibility.

For those looking for accessible options, there are nursing schools with high acceptance rates, which can be a great entry point into nursing without overly competitive admission processes. Additionally, if you’re seeking streamlined entry into nursing, consider a nursing school that doesn't require teas—eliminating the need for standardized entrance exams.

Interested in the administrative side of healthcare? Pursuing a degree in healthcare administration can open doors to leadership and management roles in hospitals and clinics. Alternatively, specialized fields such as medical billing and coding are both in demand and flexible. Look for medical billing and coding schools that accept fafsa to help ease the financial burden of your studies.

These alternative pathways offer rewarding opportunities in healthcare and can be pursued online, making them accessible and convenient for many students.

Best Scientists Citing Julie R. Brahmer

Trending Scientists

Recently Published Articles